jounce.png
Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors
20 avr. 2017 16h01 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
31 mars 2017 16h01 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 31, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics to Present at AACR Annual Meeting on JTX-2011 Cancer Immunotherapy Program
22 mars 2017 16h01 HE | Jounce Therapeutics, Inc.
-- Invited oral presentation on JTX-2011 preclinical data -- -- Poster presentation on single agent and combination trial design -- CAMBRIDGE, Mass., March 22, 2017 (GLOBE NEWSWIRE) -- Jounce...
jounce.png
Jounce Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
10 mars 2017 08h00 HE | Jounce Therapeutics, Inc.
- Completed upsized initial public offering raising $117.1 million in gross proceeds -  - Continue to advance lead product candidate JTX-2011 through Phase 1/2 ICONIC trial and to broaden new...
jounce.png
Jounce Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference
28 févr. 2017 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Announces Pricing of Initial Public Offering
26 janv. 2017 21h26 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc., a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive...
jounce.png
Jounce Therapeutics Initiates Phase 1/2 ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors
07 sept. 2016 08h30 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today...
jounce.png
Jounce Therapeutics Announces Major Strategic Collaboration with Celgene Corporation to Develop Next-generation Immuno-oncology Therapies for Patients with Cancer
19 juil. 2016 07h00 HE | Jounce Therapeutics, Inc.
Jounce to receive upfront payment of $225 million, a $36 million equity investment and up to an additional $2.3 billion in future milestone payments across all programs included in the collaboration ...
jounce.png
Jounce Therapeutics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
11 juil. 2016 08h30 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., July 11, 2016 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to a biomarker-driven...
jounce.png
Jounce Therapeutics Appoints Barbara G. Duncan to its Board of Directors
25 mai 2016 08h30 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 25, 2016 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient enrichment,...